Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HLX15-IV + lenalidomide + dexamethasone
- Development stage
- Unknown
- Lead developer
- Henlius
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A **combination therapy** consisting of HLX15-IV (a biosimilar to daratumumab), lenalidomide, and dexamethasone. HLX15-IV is a monoclonal antibody that targets CD38, a surface protein highly expressed on multiple myeloma cells, leading to cell lysis through immune-mediated mechanisms. Lenalidomide is an immunomodulatory agent that enhances immune response against myeloma cells and directly inhibits tumor cell proliferation. Dexamethasone is a synthetic corticosteroid that decreases inflammation and is cytotoxic to myeloma cells. This combination is being evaluated for the treatment of newly diagnosed multiple myeloma in patients who are ineligible for autologous stem cell transplantation[5][7][9].
- Other names
- HLX15 daratumumab biosimilar + lenalidomide + dexamethasoneHLX15-IV-RdHLX-15-IV-RdHLX 15-IV-Rd
02
Targets
GR (Glucocorticoid receptor)CD38 (Cluster of Differentiation 38)CRBN (Cereblon)
Beyond the preview
Go deeper on HLX15-IV + lenalidomide + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HLX15-IV + lenalidomide + dexamethasone.